Fiche du document
2006
- doi: 10.1158/0008-5472.CAN-05-3793
- issn: 0008-5472
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1158/0008-5472.CAN-05-3793
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/16488988
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0008-5472
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D9CFEA5BF1AA7
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Communicable diseases--Vaccination Preventive inoculation Inoculation Integument (Skin) Cutis Melanocytic tumor Malignant melanoma Carcinoma Cancers Malignancy (Cancer) Malignant tumors Preventive inoculation Diseases--VaccinationCiter ce document
P. Baumgaertner et al., « Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. », Serveur académique Lausannois, ID : 10.1158/0008-5472.CAN-05-3793
Métriques
Partage / Export
Résumé
Clinical trials have shown that strong tumor antigen-specific CD8 T-cell responses are difficult to induce but can be achieved for T-cells specific for melanoma differentiation antigens, upon repetitive vaccination with stable emulsions prepared with synthetic peptides and incomplete Freund's adjuvant. Here, we show in four melanoma patients that ex vivo detectable T-cells and thus strong T-cell responses can also be induced against the more universal cancer-testis antigens NY-ESO-1 and Mage-A10. Interestingly, all patients had ex vivo detectable T-cell responses against multiple antigens after serial vaccinations with three peptides emulsified in incomplete Freund's adjuvant. Antigen-specific T-cells displayed an activated phenotype and secreted IFNgamma. The robust immune responses provide a solid basis for further development of human T-cell vaccination.